Literature DB >> 33362774

Robust Production of Merkel Cell Polyomavirus Oncogene Specific T Cells From Healthy Donors for Adoptive Transfer.

Sarah I Davies1,2,3, John Barrett1, Susan Wong1, Mark Jesse Chang1, Pawel J Muranski1,4, Isaac Brownell3.   

Abstract

Virus positive Merkel cell carcinoma (VP-MCC) is an aggressive but immunogenic skin malignancy driven by Merkel cell polyomavirus (MCPyV) T antigen (TAg). Since adoptive T cell transfer (ACT) can be effective against virus-driven malignancies, we set out to develop a methodology for generating MCPyV TAg specific T cells. MCPyV is a common, asymptomatic infection and virus-exposed healthy donors represent a potential source of MCPyV TAg specific T cells for ACT. Virus specific T cells were generated using monocyte-derived dendritic cells (moDCs) pulsed with MCPyV TAg peptide libraries and co-cultured with autologous T cells in supplemented with pro-inflammatory and homeostatic cytokines for 14 days. Specific reactivity was observed predominantly within the CD4+ T cell compartment in the cultures generated from 21/46 random healthy donors. Notably, responses were more often seen in donors aged 50 years and older. TAg specific CD4+ T cells specifically secreted Th1 cytokines and upregulated CD137 upon challenge with MCPyV TAg peptide libraries and autologous transduced antigen presenting cells. Expanded T cells from healthy donors recognized epitopes of both TAg splice variants found in VP-MCC tumors, and minimally expressed exhaustion markers. Our data show that MCPyV specific T cells can be expanded from healthy donors using methods appropriate for the manufacture of clinical grade ACT products.
Copyright © 2020 Davies, Barrett, Wong, Chang, Muranski and Brownell.

Entities:  

Keywords:  CD4+ T-lymphocytes; adoptive; allogeneic; cellular immunity; donor; immunotherapy; skin neoplasms; translational medial research

Mesh:

Substances:

Year:  2020        PMID: 33362774      PMCID: PMC7756016          DOI: 10.3389/fimmu.2020.592721

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  53 in total

1.  Immunology. CD8 T cells remember with a little help.

Authors:  Susan M Kaech; Rafi Ahmed
Journal:  Science       Date:  2003-04-11       Impact factor: 47.728

Review 2.  The who's who of T-cell differentiation: human memory T-cell subsets.

Authors:  Yolanda D Mahnke; Tess M Brodie; Federica Sallusto; Mario Roederer; Enrico Lugli
Journal:  Eur J Immunol       Date:  2013-10-30       Impact factor: 5.532

3.  Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner.

Authors:  Lewis Zhichang Shi; Sangeeta Goswami; Tihui Fu; Baoxiang Guan; Jianfeng Chen; Liangwen Xiong; Jan Zhang; Derek Ng Tang; Xuejun Zhang; Luis Vence; Jorge Blando; James P Allison; Renata Collazo; Jianjun Gao; Padmanee Sharma
Journal:  Cancer Immunol Res       Date:  2019-08-29       Impact factor: 11.151

4.  SPICE: exploration and analysis of post-cytometric complex multivariate datasets.

Authors:  Mario Roederer; Joshua L Nozzi; Martha C Nason
Journal:  Cytometry A       Date:  2011-01-07       Impact factor: 4.355

5.  Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.

Authors:  Eric Tran; Simon Turcotte; Alena Gros; Paul F Robbins; Yong-Chen Lu; Mark E Dudley; John R Wunderlich; Robert P Somerville; Katherine Hogan; Christian S Hinrichs; Maria R Parkhurst; James C Yang; Steven A Rosenberg
Journal:  Science       Date:  2014-05-09       Impact factor: 47.728

Review 6.  Adoptive immunotherapy of cancer using CD4(+) T cells.

Authors:  Pawel Muranski; Nicholas P Restifo
Journal:  Curr Opin Immunol       Date:  2009-03-13       Impact factor: 7.486

7.  An immunogenic personal neoantigen vaccine for patients with melanoma.

Authors:  Patrick A Ott; Zhuting Hu; Derin B Keskin; Sachet A Shukla; Jing Sun; David J Bozym; Wandi Zhang; Adrienne Luoma; Anita Giobbie-Hurder; Lauren Peter; Christina Chen; Oriol Olive; Todd A Carter; Shuqiang Li; David J Lieb; Thomas Eisenhaure; Evisa Gjini; Jonathan Stevens; William J Lane; Indu Javeri; Kaliappanadar Nellaiappan; Andres M Salazar; Heather Daley; Michael Seaman; Elizabeth I Buchbinder; Charles H Yoon; Maegan Harden; Niall Lennon; Stacey Gabriel; Scott J Rodig; Dan H Barouch; Jon C Aster; Gad Getz; Kai Wucherpfennig; Donna Neuberg; Jerome Ritz; Eric S Lander; Edward F Fritsch; Nir Hacohen; Catherine J Wu
Journal:  Nature       Date:  2017-07-05       Impact factor: 49.962

8.  Allogeneic BK Virus-Specific T Cells for Progressive Multifocal Leukoencephalopathy.

Authors:  Muharrem Muftuoglu; Amanda Olson; David Marin; Sairah Ahmed; Victor Mulanovich; Sudhakar Tummala; T Linda Chi; Alessandra Ferrajoli; Indreshpal Kaur; Li Li; Richard Champlin; Elizabeth J Shpall; Katayoun Rezvani
Journal:  N Engl J Med       Date:  2018-10-11       Impact factor: 91.245

9.  Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial.

Authors:  Suzanne L Topalian; Shailender Bhatia; Asim Amin; Ragini R Kudchadkar; William H Sharfman; Celeste Lebbé; Jean-Pierre Delord; Lara A Dunn; Michi M Shinohara; Rima Kulikauskas; Christine H Chung; Uwe M Martens; Robert L Ferris; Julie E Stein; Elizabeth L Engle; Lot A Devriese; Christopher D Lao; Junchen Gu; Bin Li; Tian Chen; Adam Barrows; Andrea Horvath; Janis M Taube; Paul Nghiem
Journal:  J Clin Oncol       Date:  2020-04-23       Impact factor: 50.717

10.  CD4+ T cell exhaustion revealed by high PD-1 and LAG-3 expression and the loss of helper T cell function in chronic hepatitis B.

Authors:  Yuejiao Dong; Xuefen Li; Lu Zhang; Qiaoyun Zhu; Chunlei Chen; Jiaqi Bao; Yu Chen
Journal:  BMC Immunol       Date:  2019-08-07       Impact factor: 3.615

View more
  1 in total

1.  Zc3h12d, a Novel of Hypomethylated and Immune-Related for Prognostic Marker of Lung Adenocarcinoma.

Authors:  Bo Yang; Lin-Lin Ji; Hong-Liang Xu; Xiao-Ping Li; Hong-Gang Zhou; Ting Xiao; Xiao-He Li; Zhou-Yong Gao; Jian-Zhong Li; Wei-Dong Zhang; Guang-Shun Wang; Ming-Jiang Li
Journal:  J Inflamm Res       Date:  2021-06-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.